Drug Trial Radar · NCT00755495
Safety and Efficacy of Ramelteon and Doxepin in Subjects With Chronic Insomnia
Last checked: Nov 19, 2026Latest source record: Feb 28, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
472
Actual
Start
Jul 2006
Primary completion
Mar 2007
Study completion Mar 2007
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Sep 19, 2008
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the efficacy of ramelteon, once daily (QD), combined with doxepin in treating subjects with insomnia.
Conditions
- Sleep Initiation and Maintenance Disorders
Interventions
Ramelteon and doxepinDrug
Ramelteon 8 mg, tablets, orally, once daily and doxepin 3 mg, liquid, orally, once daily for up to five weeks.
RamelteonDrug
Ramelteon 8 mg, tablets, orally, once daily and doxepin placebo-matching liquid, orally, once daily for up to five weeks.
DoxepinDrug
Ramelteon placebo-matching tablets, orally, once daily and doxepin 3 mg, liquid, orally, once daily for up to five weeks.
PlaceboDrug
Ramelteon placebo-matching tablets, orally, once daily and doxepin placebo-matching liquid, orally, once daily for up to five weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean wake time after persistent sleep onset during the double-blind Treatment Period, as measured by polysomnographyTime frame: Weeks 1, 3, and 5 or Final Visit
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.